Xeris Biopharma Holdings (NasdaqGS:XERS) just closed FY 2025 with Q4 revenue of US$85.8 million and basic EPS of US$0.07, backed by net income of US$11.1 million. The company has seen quarterly revenue move from US$54.3 million in Q3 2024 to US$60.1 million in Q4 2024, then to US$60.1 million in Q1 2025, US$71.5 million in Q2 2025, US$74.4 million in Q3 2025, and US$85.8 million in Q4 2025, while EPS shifted from a loss of US$0.11 in Q3 2024 to EPS of US$0.07 in Q4 2025. With trailing twelve month net income edging into positive territory and revenue at US$291.8 million, the latest results point to firmer margins that investors will want to scrutinize closely.

See our full analysis for Xeris Biopharma Holdings.

Next up is how these headline numbers line up against the widely followed narratives around Xeris Biopharma Holdings, and where the story investors have in mind matches or clashes with the latest financial reality.

Revenue Nears US$300 million On Trailing Basis

• On a trailing 12 month view, total revenue reached US$291.8 million, up from US$203.1 million at the end of FY 2024. Quarterly revenue for FY 2025 moved from US$60.1 million in Q1 to US$85.8 million in Q4.
• Consensus narrative points to sustained revenue growth driven by Recorlev, Gvoke and Keveyis, and this trailing revenue step up lines up with that view, although:
  • Earnings only just moved into positive territory on a trailing basis, with net income of US$0.6 million, which means a lot of that higher revenue is still being absorbed by operating costs.
  • Bulls looking for faster expansion than the roughly 16% revenue growth forecast in the data will want to see whether this FY 2025 pace can be maintained or whether it reflects timing effects such as launch or ramp periods.

Profitability Flip Is Still Very Thin

• Xeris moved from a trailing 12 month net loss of US$54.8 million at FY 2024 to a small trailing profit of US$0.6 million by FY 2025, with quarterly net income shifting from a loss of US$15.7 million in Q3 2024 to a profit of US$11.1 million in Q4 2025.
• Bulls argue that this shows early operating leverage that could support much higher margins over time, but the current numbers leave limited room for error:
  • Trailing basic EPS is only US$0.003 on a 12 month basis, even though Q4 2025 EPS was US$0.07, so most of the profitability is concentrated late in the period rather than spread evenly.
  • The risk section notes interest payments are not well covered by earnings, so despite the move into profit, bears can point to the thin earnings base as a constraint if borrowing costs stay high or spending remains elevated.

On a quarter where Xeris only just crossed into profit, bulls and bears are looking at the same thin margin and drawing very different conclusions. It can be helpful to read how each side frames the path from US$0.6 million of trailing earnings to the much larger profit figures discussed in market forecasts. 🐂 Xeris Biopharma Holdings Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Xeris Biopharma Holdings on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of thin profits and stronger revenue leaves you unsure, that is exactly when it can be useful to look more closely and act promptly. To balance the optimism and concerns already on the table, take a moment to review the company's 4 key rewards and 1 important warning sign

See What Else Is Out There

Xeris has only just moved into a thin trailing profit, with interest costs still pressing on earnings and leaving little cushion if conditions change.

If you want stocks where financial strength is more firmly established, check out the solid balance sheet and fundamentals stocks screener (45 results) today so weaker balance sheets do not hold back your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.